The clinical impact of ICOS signal in colorectal cancer patients

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Zhang, Yan ^a   Luo, Yang ^b   Qin, Shao Lan ^b   Mu, Yi Fei ^b   Qi, Yang ^b   Yu, Min Hao ^b   Zhong, Ming ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

B7 CD28 family; Colorectal cancer; ICOS; Prognosis; Th1 cell

Indexed keywords

GAMMA INTERFERON; INDUCIBLE T CELL COSTIMULATOR LIGAND; PROGRAMMED DEATH 1 LIGAND 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; METASTASIS; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR VOLUME;

EID: 84975879195     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1141857     Document Type: Article

References (23)

1. A.H.Sharpe, G.J.Freeman. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri727
2. S.Ceeraz, E.C.Nowak, R.J.Noelle. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34:556-63; PMID:23954143; http://dx.doi.org/10.1016/j.it.2013.07.003
3. M.M.Swallow, J.J.Wallin, W.C.Sha. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999; 11:423-32; PMID:10549624; http://dx.doi.org/10.1016/S1074-7613(00)80117-X
4. J.Faget, N.Bendriss-Vermare, M.Gobert, I.Durand, D.Olive, C.Biota, T.Bachelot, I.Treilleux, S.Goddard-Leon, E.Lavergne et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi.org/10.1158/0008-5472.CAN-12-2409
5. J.Faget, V.Sisirak, J.Y.Blay, C.Caux, N.Bendriss-Vermare, C.Menetrier-Caux. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e23185; http:dx.doi.org/10.4161/onci.23185
6. A.Hutloff, A.M.Dittrich, K.C.Beier, B.Eljaschewitsch, R.Kraf, I.Anagnostopoulos, R.A.Kroczek. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717
7. A.J.Coyle, S.Lehar, C.Lloyd, J.Tian, T.Delaney, S.Manning, T.Nguyen, T.Burwell, H.Schneider, J.A.Gonzalo et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13:95-105; PMID:10933398; http://dx.doi.org/10.1016/S1074-7613(00)00011-X
8. S.Yao, Y.Zhu, G.Zhu, M.Augustine, L.Zheng, D.J.Goode, M.Broadwater, W.Ruff, S.Flies, H.Xu et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729-40; PMID:21530327; http://dx.doi.org/10.1016/j.immuni.2011.03.014
9. R.A.Droeser, C.Hirt, C.T.Viehl, D.M.Frey, C.Nebiker, X.Huber, I.Zlobec, S.Eppenberger-Castori, A.Tzankov, R.Rosso et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49:2233-42; PMID:23478000; http://dx.doi.org/10.1016/j.ejca.2013.02.015
10. P.Dalerba, C.Maccalli, C.Casati, C.Castelli, G.Parmiani. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46:33-57; PMID:12672517; http://dx.doi.org/10.1016/S1040-8428(02)00159-2
11. A.J.McAdam, T.T.Chang, A.E.Lumelsky, E.A.Greenfield, V.A.Boussiotis, J.S.Duke-Cohan, T.Chernova, N.Malenkovich, C.Jabs, V.K.Kuchroo et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000; 165:5035-40; PMID:11046032; http://dx.doi.org/10.4049/jimmunol.165.9.5035
12. M.Detheux, L.Standker, J.Vakili, J.Munch, U.Forssmann, K.Adermann, S.Pohlmann, G.Vassart, F.Kirchhoff, M.Parmentier et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 2000; 192:1501-8; PMID:11085751; http://dx.doi.org/10.1084/jem.192.10.1501
13. H.Dong, G.Zhu, K.Tamada, L.Chen. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.org/10.1038/70932
14. S.K.Yoshinaga, J.S.Whoriskey, S.D.Khare, U.Sarmiento, J.Guo, T.Horan, G.Shih, M.Zhang, M.A.Coccia, T.Kohno et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402:827-32; PMID:10617205; http://dx.doi.org/10.1038/45582
15. Y.Zhang, D.Lv, H.J.Kim, R.A.Kurt, W.Bu, Y.Li, X.Ma. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 2013; 23:394-408; PMID:23266888; http://dx.doi.org/10.1038/cr.2012.178
16. B.M.Carreno, M.Collins. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20:29-53; PMID:11861596; http://dx.doi.org/10.1146/annurev.immunol.20.091101.091806
17. H.W.Mages, A.Hutloff, C.Heuck, K.Buchner, H.Himmelbauer, F.Oliveri, R.A.Kroczek. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000; 30:1040-7; PMID:10760791; http://dx.doi.org/10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6
18. P.S.Linsley, J.Bradshaw, J.Greene, R.Peach, K.L.Bennett, R.S.Mittler. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4:535-43; PMID:8673700; http://dx.doi.org/10.1016/S1074-7613(00)80480-X
19. T.L.Walunas, D.J.Lenschow, C.Y.Bakker, P.S.Linsley, G.J.Freeman, J.M.Green, C.B.Thompson, J.A.Bluestone. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
20. T.L.Walunas, C.Y.Bakker, J.A.Bluestone. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183:2541-50; PMID:8676075; http://dx.doi.org/10.1084/jem.183.6.2541
21. G.J.Freeman, A.J.Long, Y.Iwai, K.Bourque, T.Chernova, H.Nishimura, L.J.Fitz, N.Malenkovich, T.Okazaki, M.C.Byrne et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
22. Y.Latchman, C.R.Wood, T.Chernova, D.Chaudhary, M.Borde, I.Chernova, Y.Iwai, A.J.Long, J.A.Brown, R.Nunes et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi.org/10.1038/85330
23. G.Sauter, R.Simon, K.Hillan. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003; 2:962-72; PMID:14654795; http://dx.doi.org/10.1038/nrd1254